Earnings release
Page 1
Afya Limited Announces Third Quarter and Nine Months 2025 Financial Results Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Belo Horizonte, Brazil, November 12, 2025 – Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and nine-month period, which ended September 30, 2025 (third quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2025 Highlights § 3Q25 Revenue increased 10.4% YoY to R$928.5 million. Revenue excluding acquisitions increased 10.1%, reaching R$926.2 million. § 3Q25 Adjusted EBITDA increased 14.6% YoY, reaching R$398.9 million, with an Adjusted EBITDA Margin of 43.0%. Adjusted EBITDA Margin increased 160 bps YoY. Adjusted EBITDA excluding acquisitions grew 15.2%, reaching R$400.7 million, with an Adjusted EBITDA Margin of 43.3%. § 3Q25 Net Income increased 28.4% YoY, reaching R$159.4 million, and Adjusted Net Income increased 16.5% YoY, reaching R$192.7 million. Basic EPS growth was 28.5% in the same period. Nine Months 2025 Highlights § 9M25 Revenue increased 13.4% YoY to R$2,784.3 million. Revenue excluding acquisitions grew 9.8%, reaching R$2,696.7 million. § 9M25 Adjusted EBITDA increased 18.5% YoY reaching R$1,291.7 million, with an Adjusted EBITDA Margin of 46.4%. Adjusted EBITDA Margin increased 200 bps YoY. Adjusted EBITDA excluding acquisitions grew 13.8%, reaching R$1,239.9 million, with an Adjusted EBITDA Margin of 46.0%. § 9M25 Net Income increased 19.9% YoY, reaching R$593.0 million, and Adjusted Net Income increased 11.1% YoY, reaching R$696.0 million. Basic EPS growth was 19.7% in the same period. § Operating Cash Conversion ratio of 101.5%, with a solid cash position of R$ 996.8 million. § ~304 thousand users in Afya’s ecosystem. Table 1: Financial Highlights For the three months period ended September 30, For the nine months period ended September 30, (in thousand of R$) 2025 2025 Ex Acquisitions*2024 % Chg % Chg Ex Acquisitions 2025 2025 Ex Acquisitions*2024 % Chg % Chg Ex Acquisitions (a) Revenue 928,505 926,179841,18510.4% 10.1% 2,784,265 2,696,7212,455,31413.4% 9.8% (b) Adjusted EBITDA 2 398,917 400,720347,94914.6% 15.2% 1,291,732 1,239,9081,089,62818.5% 13.8% (c) = (b)/(a) Adjusted EBITDA Margin 43.0% 43.3% 41.4%160 bps 190 bps 46.4% 46.0% 44.4%200 bps 160 bps Net income 159,420 - 124,14228.4% - 592,999 - 494,64119.9% - Adjusted Net income 192,694 - 165,37216.5% - 696,002 - 626,68311.1% - *For the three months period ended September 30, 2025, "2025 Ex Acquisitions" excludes: FUNIC (July to September, 2025; Closing of FUNIC was in May 2025). *For the nine months period ended September 30, 2025, "2025 Ex Acquisitions" excludes: UNIDOM (January to June, 2025; Closing of UNIDOM was in July 2024), and FUNIC (May to September, 2025; Closing of FUNIC was in May 2025). (2) See more information on "Non-GAAP Financial Measures" (Item 08). Message from Management This quarter demonstrates once again Afya’s ability to combine transformation with financial discipline. We advanced in initiatives that strengthen our ecosystem, and accelerate innovation, while maintaining a prudent approach to capital allocation. These achievements reinforce our confidence in the strategy and our capacity to deliver sustainable growth and long-term value for all stakeholders. We saw steady advances across our three segments, reflecting our commitment to integrate education and medical practice solutions throughout the medical journey. 1
Page 2
In Undergraduate, we concluded another intake cycle, ensuring full occupancy across all our medical schools, which reinforces Afya’s differentials and the ability to attract and retain top candidates nationwide. This approach ensures consistency in admissions, strengthens our brand positioning, and optimizes operational efficiency. In Continuing Education, we sustained impressive growth in B2B Revenue, while strengthening the graduate journey. In Medical Practice Solutions we achieved a notable increase in active payers within Clinical Management, reinforcing the value of our solutions in supporting physicians' daily practice. Our ecosystem continues to enhance learning outcomes and employability, strengthening our reputation within the medical community. We advanced AI-enabled enhancements to Afya Whitebook, iClinic and ReceitaPro further supporting clinical productivity and evidence-based decision- making at the point of care. In parallel, we launched Instituto Afya, aligned with the UN 2030 Agenda to address chronic disease challenges. Together, these initiatives strengthen our ecosystem and support long-term value creation. During October, we took coordinated actions to strengthen our capital structure. We issued commercial notes totaling R$1.5 billion in two series, maturing in 2028 and 2030, with interest rates of CDI+0.70% and CDI+0.85% per year, respectively. Using the proceeds, we repurchased all 150,000 Series A perpetual convertible preferred shares from SoftBank for R$831.6 million and fully repaid R$500 million related to Afya Participações first debenture issuance. These actions extend debt duration, and reinforce our disciplined approach to capital management. Looking ahead, we remain confident in our ability to keep delivering sustainable growth. Our integrated ecosystem, operational excellence and innovation agenda position Afya to execute with quality and consistency. We reaffirm our 2025 guidance and are proud of the progress achieved so far - energized by the opportunities ahead as we continue to transform the medical journey and physician career success in Brazil. 1. Key Events in the Quarter § On August 13, 2025, the Company’s board of directors approved a new share repurchase program. Afya may repurchase up to 4,000,000 of its outstanding Class A common shares, in the open market, based on prevailing market prices, or in privately negotiated transactions, beginning from August 15, 2025 until the early of the completion of the repurchase or December 31, 2026, depending upon market conditions. The share purchases may be made from time to time through open-market transactions and are subject to market and business conditions, levels of available liquidity, cash requirements for other purposes, regulatory, and other relevant factors. The share repurchase program will take place in accordance with the conditions established by the Board of Directors. Afya intends to repurchase the shares for use in its stock option program, consideration in futures business combinations transactions and general corporate purposes. 2. Subsequent Events § On October 15, 2025, Afya Brazil issued commercial notes for private placement ("Commercial Notes”), sold to Opea Securitizadora S.A. ("Opea”), a Brazilian securitization corporation pursuant to Section 45 of Brazilian Law No. 14,195/2021, as amended. Opea issued a debenture backed by the Commercial Notes on the same terms and conditions. The aggregate principal amount of the Commercial Notes is R$1,500,000, divided into two series, the first of which in the aggregate amount of R$500,000 ("First Series”) and the second in the aggregate amount of R$1,000,000 ("Second Series”). The First Series will mature on October 15, 2028 and the Second Series will mature on October 15, 2030. The interest rate applicable to the First Series and Second Series will be equal to CDI plus a spread of 0.70% and 0.85% per year, respectively, based on 252 business days. The Commercial Notes are subject to certain obligations including financial covenants, and the Company shall maintain net debt (excluding lease liabilities) to adjusted EBITDA ratio below or equal to 3.0 x, at the end of each fiscal year, until maturity date, applicable from December 31, 2025 and thereafter. Adjusted EBITDA considers net income plus (i) income taxes expenses, (ii) net financial result (excluding interest expenses on lease liabilities), (iii) depreciation and amortization expenses (excluding right-of-use assets depreciation expenses), (iv) share-based compensation expenses, (v) share of income of associate, (vi) interest received and (vii) non-recurring expenses. 2
Page 3
The Commercial Notes has sureties provided by the following subsidiaries of the Company: Unigranrio, IESP and DelRey. § On October 22, 2025, Afya Brazil fully repaid the aggregate outstanding amount related to the first issuance of debentures originally issued on December 16, 2022. The debentures were issued with a final maturity date of January 15, 2028, with the principal to be amortized in two equal installments payable on January 15, 2027, and January 15, 2028. § On November 3, 2025, the Company repurchased all 150,000 Series A perpetual convertible preferred shares of a nominal or par value of US$0.00005 each in the capital of the Company ("Series A Preferred Shares") for an aggregate purchase price of R$831,600, following the Share Repurchase Agreement with SBLA Holdco LLC, an affiliate of Softbank. All repurchased Series A Preferred Shares were cancelled by the Company. § On November 7, 2025, MEC authorized the increase of 100 medical school seats of ITPAC Porto located in the city of Bragança, State of Pará. With this authorization, Afya reaches 150 medical school seats on this campus, and 3,753 total approved medical school seats. 3. 2025 Guidance The Company is reaffirming its guidance for 2025, as defined in the following table, which considers the successful acceptance of new students for the second semester of 2025: Guidance for 2025 Revenue R$ 3,670 mn ≤ ∆ ≤ R$ 3,770 mn Adjusted EBITDA R$ 1,620 mn ≤ ∆ ≤ R$ 1,720 mn CAPEX 1 R$ 250 mn ≤ ∆ ≤ R$ 290 mn (1) Excludes the license CAPEX related to the acquisition of FUNIC. 4. 3Q25 Overview Segment Information The Company has three reportable segments as follows: Undergraduate, which provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex- health undergraduate programs. Continuing education, which provides medical education (including residency preparation programs, specialization test preparation and other medical capabilities), specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical Practice Solutions, which provides clinical decision, clinical management and doctor-patient relationships for physicians and provides access, demand and efficiency for the healthcare players. 3
Page 4
Key Revenue Drivers – Undergraduate Programs Table 2: Key Revenue Drivers Nine months period ended September 30, 2025 2024 % Chg Undergraduate Programs MEDICAL SCHOOL Approved Seats 3,653 3,593 1.7% Operating Seats 1 3,603 3,543 1.7% Total Students (end of period) 25,706 24,234 6.1% Average Total Students 25,773 23,168 11.2% Average Total Students (ex-Acquisitions)* 24,683 23,168 6.5% Revenue (Total - R$ '000) 2,112,619 1,843,545 14.6% Revenue (ex- Acquisitions* - R$ '000) 2,030,656 1,843,545 10.1% Medical School Net Avg. Ticket (ex- Acquisitions* - R$/month) 9,141 8,841 3.4% UNDERGRADUATE HEALTH SCIENCE Total Students (end of period) 26,980 25,950 4.0% Average Total Students 26,276 25,028 5.0% Average Total Students (ex-Acquisitions)* 25,757 25,028 2.9% Revenue (Total - R$ '000) 193,656 177,053 9.4% Revenue (ex- Acquisitions* - R$ '000) 191,520 177,053 8.2% OTHER EX- HEALTH UNDERGRADUATE Total Students (end of period) 35,074 27,855 25.9% Average Total Students 34,386 27,745 23.9% Average Total Students (ex-Acquisitions)* 33,409 27,745 20.4% Revenue (Total - R$ '000) 152,938 135,296 13.0% Revenue (ex- Acquisitions* - R$ '000) 149,493 135,296 10.5% Total Revenue Revenue (Total - R$ '000) 2,459,213 2,155,895 14.1% Revenue (ex- Acquisitions* - R$ '000) 2,371,669 2,155,895 10.0% *For the nine months period ended September 30, 2025, "2025 Ex Acquisitions" excludes: UNIDOM (January to June, 2025; Closing of UNIDOM was in July 2024), and FUNIC (May to September, 2025; Closing of FUNIC was in May 2025). (1) The difference between approved and operating seats refers to Cametá, a campus that is still pre-operational. 4
Page 5
Key Revenue Drivers – Continuing Education Table 3: Key Revenue Drivers Nine months period ended September 30, 2025 2024 % Chg Continuing Education Total Studends (end of period)1 Residency Journey - Business to Physicians B2P 9,969 15,678 -36.4% Graduate Journey - Business to Physicians B2P 9,180 7,293 25.9% Other Courses - B2P and B2B Offerings 31,168 29,780 4.7% Total Students (end of period) 50,317 52,751 -4.6% Revenue (R$ '000) Business to Physicians - B2P 186,625 175,002 6.6% Business to Business - B2B 20,993 12,730 64.9% Total Revenue 207,618 187,731 10.6% (1) The figure above does not contemplate intercompany transactions Key Revenue – Medical Practice Solutions Table 4: Key Revenue Drivers Nine months period ended September 30, 2025 2024 % Chg Medical Practice Solutions Active Payers (end of period) Clinical Decision 157,963 166,780 -5.3% Clinical Management 37,523 33,503 12.0% Total Active Payers (end of period) 195,486 200,283 -2.4% Monthly Active Users (MaU) Total Monthly Active Users (MaU) 227,941 248,775 -8.4% Revenue (R$ '000)1 Business to Physicians - B2P 114,081 102,812 11.0% Business to Business - B2B 14,111 14,478 -2.5% Total Revenue 128,193 117,290 9.3% (1) Revenue from 'Shosp', the clinical management software, was reclassified from B2B to B2P. Key Operational Drivers – Users Positively Impacted by Afya The Users Positively Impacted by Afya represents the total number of medical students from the Undergraduate segment, students from the Continuing Education and users from Medical Practice Solutions. For the third quarter of 2025, Afya’s ecosystem reached 303,964 users. 5
Page 6
Table 5: Key Revenue Drivers Nine months period ended September 30, 2025 2024 % Chg Users Positively Impacted by Afya 1 Undergraduate (Total Medical School Students - End of Period) 25,706 24,234 6.1% Continuing Education (Total Students - End of Period) 50,317 52,751 -4.6% Medical Practice Solutions (Monthly Active Users) 227,941 248,775 -8.4% Ecosystem Outreach 303,964 325,760 -6.7% (1) Ecosystem outreach does not contemplate intercompany figures. Note that there may be overlap in student numbers within the data. Seasonality of Operations Undergraduate tuition revenues are related to the intake process, and monthly tuition fees charged to students and do not significantly fluctuate during each semester. Continuing education revenues are mostly related to: (i) monthly intakes and tuition fees on medical education, which do not have a considerable concentration in any period; (ii) Residency journey product revenues, derived from e-books transferred at a point of time, which are concentrated at in the first and last quarter of the year due to the enrollments. Medical Practice Solutions are comprised mainly of Afya Whitebook and Afya iClinic revenues, which do not have significant fluctuations regarding seasonality. Revenue Revenue for the third quarter of 2025 was R$928.5 million, an increase of 10.4% over the same period in the prior year. For the nine-month period ended September 30, 2025, Revenue was R$2,784.3 million, reflecting a 13.4% increase over the same period of last year. Excluding acquisitions, Revenue in the third quarter increased by 10.1% YoY to R$926.2 million. For the nine-month period ended September 30, 2025, excluding acquisitions, Revenue was R$2,696.7 million, reflecting a 9.8% increase over the same period of last year. The quarter revenue growth was mainly driven by (a) Undergraduate, higher tickets in medicine courses, the maturation of medical school seats and the acquisition of FUNIC; (b) Continuing Education, expansion in Graduate Journey students, increasing the average ticket per student across the segment; and (c) Medical Practice Solutions, which delivered growth primarily due to an expansion in Clinical Management active payers and a more favorable product mix. Table 6: Revenue & Revenue Mix (in thousands of R$) For the three months period ended September 30, For the nine months period ended September 30, 2025 2025 ExAcquisitions* 2024 % Chg % Chg ExAcquisitions 2025 2025 ExAcquisitions* 2024 % Chg % Chg ExAcquisitions Revenue Mix Undergraduate 817,712 815,386 741,729 10.2% 9.9% 2,459,213 2,371,669 2,155,895 14.1% 10.0% Continuing Education 70,098 70,098 60,225 16.4% 16.4% 207,618 207,618 187,731 10.6% 10.6% Medical Practice Solutions 44,189 44,189 40,436 9.3% 9.3% 128,193 128,193 117,290 9.3% 9.3% Inter-segment transactions (3,494) (3,494) (1,205) 190.0% 190.0% (10,759) (10,759) (5,602) 92.1% 92.1% Total Reported Revenue 928,505 926,179 841,185 10.4% 10.1% 2,784,265 2,696,721 2,455,314 13.4% 9.8% *For the three months period ended September 30, 2025, "2025 Ex Acquisitions" excludes: FUNIC (July to September, 2025; Closing of FUNIC was in May 2025). *For the nine months period ended September 30, 2025, "2025 Ex Acquisitions" excludes: UNIDOM (January to June, 2025; Closing of UNIDOM was in July 2024), and FUNIC (May to September, 2025; Closing of FUNIC was in May 2025). Adjusted EBITDA Adjusted EBITDA for the third quarter of 2025 increased by 14.6% to R$398.9 million, up from R$347.9 million in the same period of the prior year, with the Adjusted EBITDA Margin rising by 160 basis points to 43.0%. For the nine-month period ended September 30, 2025, Adjusted EBITDA was R$1,291.7 million, an increase of 18.5% over the same period of the prior year, accompanied by an Adjusted EBITDA Margin increase of 200 basis points in the same period. 6
Page 7
The increase in Adjusted EBITDA Margin was mainly driven by: (a) higher gross margin in the Undergraduate and Continuing Education segments; (b) restructuring initiatives within Continuing Education and Medical Practice Solutions; and (c) improved efficiency in Selling, General, and administrative expenses. Table 7: Reconciliation between Adjusted EBITDA and Net Income (in thousands of R$) For the three months period ended September30, For the nine months period ended September 30, 2025 2024 % Chg 2025 2024 % Chg Net income 159,420 124,142 28.4% 592,999 494,641 19.9% Net financial result 99,583 99,844 -0.3% 289,386 242,761 19.2% Income taxes expense 21,221 12,432 70.7% 63,470 26,388 140.5% Depreciation and amortization 94,657 85,828 10.3% 281,110 249,135 12.8% Interest received 1 15,179 13,945 8.8% 39,921 34,979 14.1% Income share associate (2,791) (2,526) 10.5% (10,667) (9,726) 9.7% Share-based compensation 4,163 5,871 -29.1% 16,683 26,299 -36.6% Non-recurring expenses: 7,485 8,413 -11.0% 18,830 25,151 -25.1% - Integration of new companies 2 6,981 6,444 8.3% 17,769 17,722 0.3% - M&A advisory and due diligence 3 268 1,220 -78.0% 560 2,803 -80.0% - Expansion projects 4 236 198 19.2% 489 2,568 -81.0% - Restructuring expenses 5 - 551 n.a. 12 2,058 -99.4% Adjusted EBITDA 398,917 347,949 14.6% 1,291,732 1,089,628 18.5%Adjusted EBITDA Margin 43.0% 41.4% 160 bps 46.4% 44.4% 200 bps (1) Represents the interest received on late payments of monthly tuition fees.(2) Consists of expenses related to the integration of newly acquired companies.(3) Consists of expenses related to professional and consultant fees in connection with due diligence services for our M&A transactions.(4) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses.(5) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of our acquired companies. Net Income Net Income for the third quarter of 2025, totaled R$159.4 million, reflecting an 28.4% increase YoY. Adjusted Net Income reached R$192.7 million, an increase of 16.5% over the same period in the prior year. For the nine-month period, Afya achieved a Net Income of R$593.0 million, 19.9% higher than the same period of 2024, and an Adjusted Net Income of R$696.0 million, which was 11.1% higher than the previous period. This growth reflects stronger operational performance, combined with the recognition of deferred tax assets, partially offset by the additional CSLL provision related to the OECD’s Pillar Two global minimum tax effects. Basic EPS for the nine-month period ended September 30, 2025, reached R$6.40. An increase of 19.7% YoY, reflecting the higher Net Income. 7
Page 8
Table 8: Adjusted Net Income (in thousands of R$) For the three months period ended September30, For the nine months period ended September 30, 2025 2024 % Chg 2025 2024 % Chg Net income 159,420 124,142 28.4% 592,999 494,641 19.9% Amortization of Intangible Assets 1 21,626 26,946 -19.7% 67,490 80,592 -16.3% Share-based compensation 4,163 5,871 -29.1% 16,683 26,299 -36.6% Non-recurring expenses: 7,485 8,413 -11.0% 18,830 25,151 -25.1% - Integration of new companies 2 6,981 6,444 8.3% 17,769 17,722 0.3% - M&A advisory and due diligence 3 268 1,220 -78.0% 560 2,803 -80.0% - Expansion projects 4 236 198 19.2% 489 2,568 -81.0% - Restructuring expenses 5 - 551 n.a. 12 2,058 -99.4% Adjusted Net Income 192,694 165,372 16.5% 696,002 626,683 11.1% Basic earnings per share - in R$ 6 1.71 1.33 28.5% 6.40 5.35 19.7% Adjusted earnings per share - in R$ 7 2.08 1.79 16.2% 7.54 6.81 10.7% (1) Consists of amortization of intangible assets identified in business combinations.(2) Consists of expenses related to the integration of newly acquired companies.(3) Consists of expenses related to professional and consultant fees in connection with due diligence services for our M&A transactions.(4) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses.(5) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of our acquired companies.(6) Basic earnings per share: Net Income/Weighted average number of outstanding shares.(7) Adjusted earnings per share: Adjusted Net Income attributable to equity holders of the Parent/Weighted average number of outstanding shares. Cash and Debt Position As of September 30, 2025, Cash and Cash Equivalents totaled R$996.8 million, representing a 9.4% increase from December 31, 2024. Afya reduced its Net Debt, excluding the effect of IFRS 16, to R$1,342.2 million, a decrease of R$472.7 million compared to December 31, 2024. This reduction was achieved through solid Cash Flow from Operating Activities, despite the business combination with FUNIC, dividend payments, and Afya’s share repurchase program. For the nine-month period ended September 30, 2025, Afya generated R$1,291.5 million in Cash Flow from Operating Activities, up from R$1,167.5 million in the same period of the previous year, an increase of 10.6% YoY, boosted by operational results. The Operating Cash Conversion Ratio reached 101.5%. 8
Page 9
Table 9: Operating Cash Conversion Ratio Reconciliation For the nine months period ended September 30, (in thousands of R$) Considering the adoption of IFRS 16 2025 2024 % Chg (a) Net cash flows from operating activities 1,277,763 1,148,175 11.3% (b) Income taxes paid 13,712 19,290 -28.9% (c) = (a) + (b) Cash flow from operating activities 1,291,475 1,167,465 10.6% (d) Adjusted EBITDA 1,291,732 1,089,628 18.5% (e) Non-recurring expenses: 18,830 25,151 -25.1% - Integration of new companies 1 17,769 17,722 0.3% - M&A advisory and due diligence 2 560 2,803 -80.0% - Expansion projects 3 489 2,568 -81.0% - Restructuring Expenses 4 12 2,058 -99.4% (f) = (d) - (e) Adjusted EBITDA ex- non-recurring expenses 1,272,902 1,064,477 19.6% (g) = (c) / (f) Operating cash conversion ratio 101.5% 109.7% -820 bps (1) Consists of expenses related to the integration of newly acquired companies. (2) Consists of expenses related to professional and consultant fees in connection with due diligence services for M&A transactions.(3) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses.(4) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of acquired companies. The following table shows more information regarding the cost of debt for 9M25, considering loans and financing and accounts payable to selling shareholders. Afya’s capital structure remains solid, with a conservative leveraging position and a low cost of debt. Afya’s Net Debt (excluding the effect of IFRS16) divided by Adjusted EBITDA mid guidance for 2025 would be 0.8x, marking an impressive reduction from 1.3x in the same period of the prior year, and a sequential reduction from 0.97x in the previous quarter, reinforcing Afya’s accelerated deleveraging trend. The issuance of R$1,500 million in debentures on October 15, 2025, together with the prepayment of the SoftBank convertible, the first issuance of debentures by Afya Participações S.A., and other Loans and Financing, demonstrate Afya’s disciplined approach to capital allocation and proactive liability management, resulting in an extended average debt duration of 3.2 years on a pro forma basis. Table 10: Gross Debt and Average Cost of Debt (in millions of R$) For the closing of the nine months period ended in September 30, Cost of Debt Gross Debt Duration (Years) Per year %CDI² 2025 2024 2025 2024 2025 2024 2025 2024 Loans and financing: Softbank 863 828 0.6 1.6 9.1% 6.5% 66% 51% Loans and financing: Debentures 516 511 1.8 2.8 16.1% 12.1% 113% 112% Loans and financing: Others 6 309 1.0 1.0 8.6% 12.8% 63% 119% Loans and financing: IFC 529 497 3.1 4.1 15.3% 11.8% 108% 110% Accounts payable to selling shareholders 425 586 3.7 3.3 14.4% 10.7% 102% 100% Total¹| Average 2,339 2,731 1.9 2.6 13.0% 9.4% 93% 88% (1) Total ammount refers only to the "Gross Debt" columns.(2) Based on the annualized Interbank Certificates of Deposit ("CDI") rate for the period as a reference: 9M25: ~14.90% p.y. and for 9M24: ~10.65% p.y. 9
Page 10
Table 11: Cash and Debt Position (in thousands of R$) 3Q25 FY2024 % Chg 3Q24 % Chg (+) Cash and Cash Equivalents 996,826 911,015 9.4% 836,876 19.1% Cash and Bank Deposits 8,609 6,078 41.6% 5,594 53.9% Cash Equivalents 988,217 904,937 9.2% 831,282 18.9% (-) Loans and Financing 1,913,667 2,195,161 -12.8% 2,145,270 -10.8% Current 916,828 363,554 152.2% 30,051 2950.9% Non-Current 996,839 1,831,607 -45.6% 2,115,219 -52.9% (-) Accounts Payable to Selling Shareholders 425,331 530,772 -19.9% 586,042 -27.4% Current 106,810 185,318 -42.4% 247,192 -56.8% Non-Current 318,521 345,454 -7.8% 338,850 -6.0% (-) Other Short and Long Term Obligations - - n.a. - n.a. (=) Net Debt (Cash) excluding IFRS 16 1,342,172 1,814,918 -26.0% 1,894,436 -29.2% (-) Lease Liabilities 1,060,905 978,336 8.4% 974,780 8.8% Current 52,561 45,580 15.3% 45,133 16.5% Non-Current 1,008,344 932,756 8.1% 929,647 8.5% Net Debt (Cash) with IFRS 16 2,403,077 2,793,254 -14.0% 2,869,216 -16.2% CAPEX Capital expenditure consists of the purchase of property and equipment and intangible assets, including expenditure mainly related to the expansion and maintenance of Afya’s campuses and headquarters, leasehold improvements, and the development of new solutions in the Medical Practice Solutions and content in the Continuing Education. For the nine-month period ended September 30, 2025, CAPEX totaled R$ 303.2 million. Excluding the license payment related to the FUNIC acquisition, CAPEX was R$ 203.5 million, representing 7.3% of Afya’s revenue for the period. Table 12: CAPEX (in thousands of R$) For the nine months period ended September 30, 2025 2024 % Chg CAPEX 303,154 316,766 -4.3% Property and equipment 123,641 93,367 32.4% Intangible assets 179,513 223,399 -19.6% - Licenses1 99,629 157,227 -36.6% - Others 79,884 66,172 20.7% (1) One-off effects include: (i) R$ 99.6 million in May 2025, related to the acquisition of FUNIC, which added 60 medical seats; (ii) R$ 49.6 million in January 2024, related to the earn-out of FIP Guanambi, following the expansion of 40 medical seat, and (iii) R$107.6 million in July 2024, related to the earn-out of UNIMA, due to the expansion of 80 seats. 10
Page 11
ESG Metrics ESG commitment is a crucial part of Afya’s strategy and is deeply ingrained in the Company’s core values. Afya has been advancing year after year on its core pillars and, since 2021, ESG metrics have been disclosed in the Company’s quarterly financial results in three key metrics, Governance and Employee Management, Environmental and Social. The 2024 Sustainability Report can be found at: https://ir.afya.com.br/annual-report/ Table 13: ESG Metrics 1, 2 & 3 3Q25 3Q24 2024 2023 # GRI Governance and Employee Management 1 405-1 Number of employees 9,801 10,155 9,717 9,680 2 405-1 Percentage of female employees 60% 59% 59% 58% 3 405-1 Percentage of female employees in the board of directors 30% 30% 30% 36% 4 102-24 Percentage of independent member in the board of directors 40% 40% 40% 36% Environmental 5 Total renewable energy generated by own photovoltaic plants (MWh) 1,357.671 1,471.476 6,329.796 4,510.637 6 302-1 Total energy consumed (MWh) 6,259.079 5,644.403 24,260.662 24,036.608 7 302-1 % of renewable energy consumed from own generation 18.5% 22.5% 23.2% 16.0% 8 302-1 % of energy consumed from the power grid 31.2% 37.6% 34.8% 60.3% 9 302-1 % of energy consumed from the free market 50.3% 39.9% 42.0% 23.7% Social 10 413-1 Number of free clinical consultations offered by Afya 257,630 221,230 846,264 586,611 11 Number of physicians graduated in Afya's campuses 24,610 21,266 22,867 20,197 12 201-4 Number of students with financing and scholarship programs (FIES and PROUNI) 15,836 11,636 12,342 10,584 13 % students with scholarships over total undergraduate students 18.0% 14.9% 16.0% 16.0% 14 413-1 Hospital, clinics and city halls partnerships 638 567 614 649 (1) Some factors can influence in the adequate proportionality analysis of data over the years, such as: climate changes, COVID-19 pandemic effects, seasonalities, number of employees, number of students, number of active units, among others. (2) Starting in 2Q22, previously disclosed social data were updated to consider: (a) the number of graduated physicians considering all units after its closing, and (b) partnerships related only to medical schools. (3) The number of students with financing and scholarship programs (FIES and PROUNI) in 2023 excludes students from the Unima and FCM Jaboatão acquisition. As of 2Q25, it also includes students from the UNIDOM acquisition. 5. Conference Call and Webcast Information When: November 12, 2025 at 5:00 p.m. EST. Who: Mr. Virgilio Gibbon, Chief Executive Officer Mr. Luis André Blanco, Chief Financial Officer Ms. Renata Costa Couto, IR Director Webcast: https://afya.zoom.us/j/99527431135 OR Dial-in: Brazil: +55 11 4632 2236 or +55 11 4632 2237 or +55 11 4680 6788 or +55 11 4700 9668 or +55 21 3958 7888. United States: +1 346 248 7799 or +1 360 209 5623 or+1 386 347 5053 or +1 507 473 4847 or +1 564 217 2000 or +1 646 931 3860 or +1 669 444 9171 or +1 669 900 6833 or +1 689 278 1000 or +1 719 359 4580 or +1 929 205 6099 or +1 253 205 0468 or +1 253 215 8782 or +1 301 715 8592 or +1 305 224 1968 or +1 309 205 3325 or +1 312 626 6799. Webinar ID: 995 2743 1135 Other Numbers: https://afya.zoom.us/u/advMyerzrb 11
Page 12
6. About Afya Limited (Nasdaq: AFYA; B3: A2FY34) Afya is a leading medical education group in Brazil based on the number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and offering medical practice solutions to help doctors enhance their healthcare services through their whole career. For more information, please visit www.afya.com.br. 7. Forward – Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. All statements other than statements of historical fact could be deemed forward-looking, including risks and uncertainties related to statements about our competition; our ability to attract, upsell and retain students; our capacity to increase tuition prices; our ability to anticipate and meet the evolving needs of students and teachers; our capacity to source and successfully integrate acquisitions; as well as general market, political, economic, and business conditions. Additionally, these statements include financial targets such as revenue, share count and IFRS and non-IFRS financial measures including gross margin, operating margin, net income (loss) per diluted share, and free cash flow. These statements are not guarantees of future performance and undue reliance should not be placed on them. The Company assumes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances occurring after its publication, nor to incorporate new information or the occurrence of unanticipated events, except as required by law. The achievement or success of the matters covered by such forward-looking statements involves known and unknown risks, uncertainties and assumptions. If any of these risks or uncertainties materialize or if any of the assumptions prove incorrect, our results could differ materially from those expressed or implied by the forward- looking statements we make. Readers should not rely upon forward-looking statements as predictions of future events. Forward-looking statements represent management’s beliefs and assumptions only as of the date they are made. Further information on these and other factors that could affect the Company’s financial results is included in filings made with the United States Securities and Exchange Commission (SEC) from time to time, including the section titled “Risk Factors” in the most recent annual report on Form 20-F. These documents are available in the SEC Filings section of the investor relations section of our website at: https://ir.afya.com.br/. 8. Non-GAAP Financial Measures To supplement the Company's consolidated financial statements, which are prepared and presented in accordance with IFRS accounting standards as issued by the International Accounting Standards Board—IASB, Afya presents Adjusted EBITDA, Operating Cash Conversion Ratio, Adjusted Net Income and Adjusted EPS, which are non-GAAP financial measures, for the convenience of investors. A non-GAAP financial measure is generally defined as one that intends to measure financial performance but excludes or includes amounts that would not be equally adjusted in the most comparable GAAP measure. Afya calculates Adjusted EBITDA as net income plus/minus net financial result, plus income taxes expense, plus depreciation and amortization, plus interest received on late payments of monthly tuition fees, plus share-based compensation, plus/minus income share associate, plus/minus non-recurring expenses/income. Operating Cash Conversion Ratio is calculated as the Cash flow from Operating Activities plus income taxes paid, minus/plus non- recurring expenses/income divided by Adjusted EBITDA. The calculation of Adjusted Net Income is the Net Income plus amortization of customer relationships and trademark, plus share-based compensation, plus/minus non-recurring expenses/income. The calculation of Adjusted EPS is the Adjusted Net Income minus the non-controlling interests divided by the Weighted average number of outstanding shares. The non-GAAP supplemental financial measures are provided with the intend to help investors in assessing the overall performance of Afya’s business regarding its core operations, cash generation and profitability. The non-GAAP financial measures described in this release are not substitutes for the IFRS measures. In addition, the calculations of Adjusted EBITDA, Operating Cash Conversion Ratio, Adjusted Net Income and Adjusted EPS are not standardized financial measures and may differ from the calculations used by other companies, including competitors in the education services industry, and therefore, Afya’s measures may not be comparable to those of other companies. 12
Page 13
9. Investor Relations Contact E-mail: ir@afya.com.br 10. Financial Tables Unaudited interim condensed consolidated statements of financial positionAs of September 30, 2025 and December 31, 2024 (In thousands of Brazilian reais) September 30, 2025 December 31, 2024 Assets (unaudited) Current assets Cash and cash equivalents 996,826 911,015 Trade receivables 671,177 595,898 Recoverable taxes 24,700 21,740 Income taxes recoverable 21,046 3,986 Other assets 48,525 57,145 Total current assets 1,762,274 1,589,784 Non-current assets Trade receivables 33,597 35,948 Deferred tax assets 40,826 - Other assets 123,893 115,875 Investment in associate 56,307 54,442 Property and equipment 695,231 658,482 Right-of-use assets 900,305 842,219 Intangible assets 5,574,726 5,532,789 Total non-current assets 7,424,885 7,239,755 Total assets 9,187,159 8,829,539 Liabilities Current liabilities Trade payables 142,318 128,080 Loans and financing 916,828 363,554 Lease liabilities 52,561 45,580 Accounts payable to selling shareholders 106,810 185,318 Advances from customers 147,037 161,048 Dividends payable 825 - Labor and social obligations 286,575 208,076 Taxes payable 35,827 33,456 Income taxes payable 104,374 4,247 Other liabilities 7,116 10,836 Total current liabilities 1,800,271 1,140,195 Non-current liabilities Loans and financing 996,839 1,831,607 Lease liabilities 1,008,344 932,756 Accounts payable to selling shareholders 318,521 345,454 Taxes payable 107,061 112,681 Provision for legal proceedings 124,844 113,521 Other liabilities 44,687 42,742 Total non-current liabilities 2,600,296 3,378,761 Total liabilities 4,400,567 4,518,956
Page 14
Equity Share capital 17 17 Additional paid-in capital 2,320,422 2,344,521 Treasury shares (240,136) (273,955) Share-based compensation reserve 204,180 187,497 Retained earnings 2,461,590 2,011,875 Equity attributable to equity holders of the parent 4,746,073 4,269,955 Non-controlling interests 40,519 40,628 Total equity 4,786,592 4,310,583 Total liabilities and equity 9,187,159 8,829,539 13
Page 15
Unaudited interim condensed consolidated statements of income and comprehensive incomeFor the three and nine-month periods ended September 30, 2025 and 2024 (In thousands of Brazilian reais, except for earnings per share information) Three-month period ended Nine-month period ended September 30, 2025 September 30, 2024 September 30, 2025 September 30, 2024 (unaudited) (unaudited) (unaudited) (unaudited) Revenue 928,505 841,185 2,784,265 2,455,314 Cost of services (339,916) (324,083) (965,262) (908,429) Gross profit 588,589 517,102 1,819,003 1,546,885 Selling, general and administrative expenses (286,162) (268,456) (827,480) (743,364) Allowance for expected credit losses (18,082) (11,571) (51,135) (41,589) Other income 3,263 9,460 9,497 10,491 Other expenses (10,175) (12,643) (14,697) (18,359) Operating income 277,433 233,892 935,188 754,064 Finance income 59,185 30,396 143,663 79,659 Finance expenses (158,768) (130,240) (433,049) (322,420) Net finance result (99,583) (99,844) (289,386) (242,761) Share of income of associate 2,791 2,526 10,667 9,726 Income before income taxes 180,641 136,574 656,469 521,029 Income taxes expenses Current (36,734) (9,198) (104,296) (23,154) Deferred 15,513 (3,234) 40,826 (3,234) Net income 159,420 124,142 592,999 494,641 Other comprehensive income - - - - Total comprehensive income 159,420 124,142 592,999 494,641 Income attributable to: Equity holders of the parent 155,167 119,979 579,499 481,583 Non-controlling interests 4,253 4,163 13,500 13,058 159,420 124,142 592,999 494,641 Basic earnings per common share 1.71 1.33 6.40 5.35 Diluted earnings per common share 1.70 1.31 6.34 5.28 14
Page 16
Unaudited interim condensed consolidated statements of cash flowsFor the nine-month periods ended September 30, 2025 and 2024(In thousands of Brazilian reais) September 30, 2025 September 30, 2024 (unaudited) (unaudited) Operating activities Income before income taxes 656,469 521,029Adjustments to reconcile income before income taxes Depreciation and amortization expenses 281,110 249,135 Write-off of property and equipment 3,149 2,108Write-off of intangible assets 7 243 Allowance for expected credit losses 51,135 41,589 Share-based compensation expense 16,683 26,299Net foreign exchange differences 2,430 7,462 Accrued interest 248,290 166,343 Accrued interest on lease liabilities 91,414 82,803Share of income of associate (10,667) (9,726) Provision for legal proceedings 18,980 6,840 Changes in assets and liabilities Trade receivables (124,063) (35,619) Recoverable taxes (20,020) 2,409Other assets (1,846) 21,254 Trade payables 14,238 19,966 Taxes payable 1,409 (6,625)Advances from customers (14,011) 40 Labor and social obligations 78,499 69,719Provision for legal proceedings (5,209) (2,221) Other liabilities 3,478 4,417 1,291,475 1,167,465 Income taxes paid (13,712) (19,290) Net cash flows from operating activities 1,277,763 1,148,175 Investing activities Acquisition of property and equipment (123,641) (93,367) Acquisition of intangibles assets (139,513) (223,399)Dividends received 8,802 6,195 Acquisition of subsidiaries, net of cash acquired (144,076) (579,074) Payments of interest from acquisition of subsidiaries and intangibles (49,608) (55,898) Net cash flows used in investing activities (448,036) (945,543) Financing activities Payments of principal of loans and financing (301,692) (126,666) Payments of interest of loans and financing (185,230) (156,897) Proceeds from loans and financing - 492,351Payments of principal of lease liabilities (36,869) (30,218) Payments of interest of lease liabilities (89,732) (82,567) Proceeds from exercise of stock options 25,733 6,041Treasury shares repurchase (11,128) - Dividends paid (142,568) (13,368) Net cash flows (used) generated in financing activities (741,486) 88,676 Net foreign exchange differences (2,430) (7,462) Net increase in cash and cash equivalents 85,811 283,846 Cash and cash equivalents at the beginning of the period 911,015 553,030Cash and cash equivalents at the end of the period 996,826 836,876 15